New Insights into Monocyte-Derived Macrophages in Glioblastoma
Research · 2025-01 · 8
DOI: 10.34133/research.0836 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 12.08.2025. Verfasst von Xuetong Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Key Research and Development Plan of Hunan Province, Scientific Research Program of FuRong Laboratory.
Abstract (Originalsprache)
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by an immunosuppressive microenvironment that importantly contributes to treatment resistance. Monocyte-derived macrophages (MDMs), which comprise approximately 50% of the cellular population within the GBM microenvironment, represent a major subset of tumor-associated macrophages. These cells drive tumor progression by promoting angiogenesis, immune evasion, and the phenotypic transformation of tumor cells. MDM infiltration is mediated by specific signaling pathways and regulated by the disruption of the blood–brain barrier and tumor-associated hypoxia. Recent technological advances have uncovered substantial heterogeneity among macrophages, including hypoxia-induced, lipid-metabolizing, phagocytic, and interferon-activated subtypes. This functional diversity is shaped by tumor-specific genetic alterations and metabolic reprogramming. Therapeutic approaches focusing on MDMs include inhibiting their recruitment, enhancing phagocytic activity, employing genetically engineered macrophage, and modulating metabolic pathways. While preclinical studies suggest that these approaches may improve efficacy when combined with immune checkpoint inhibitors, the dynamic spatiotemporal heterogeneity and adaptability of macrophages within the tumor microenvironment remain substantial therapeutic challenges. Future development in combination therapies, integrating single-cell multi-omics, spatial metabolic profiling, and targeted interventions, will be critical to precisely modulate MDMs, overcome immune tolerance, and improve patient outcomes.
Autor:innen und Institutionen
- The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
- The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medicine,…
- Xiangya School of Public Health, Central South University, Changsha, China.
ORCID-Profile: Minghua Wu
Förderung
- National Natural Science Foundation of China
- Key Research and Development Plan of Hunan Province
- Scientific Research Program of FuRong Laboratory
- Changsha Natural Science Foundation
- Fundamental Research Funds for the Central Universities of Central South University
- Biomedical Center of Central South University Institute for Advanced Study, and the Graduate Research and Innovation Projects of Hunan Province
Zitieren
APA
Li, X., Gao, W., Long, X., & Wu, M. (2025). New Insights into Monocyte-Derived Macrophages in Glioblastoma. Research, 8. https://doi.org/10.34133/research.0836
Vancouver
Li X, Gao W, Long X, Wu M. New Insights into Monocyte-Derived Macrophages in Glioblastoma. Research. 2025;8. doi:10.34133/research.0836
BibTeX
@article{Li2025,
author = {Li, Xuetong and Gao, Wei and Long, Xinmiao and Wu, Minghua},
title = {New Insights into Monocyte-Derived Macrophages in Glioblastoma},
journal = {Research},
year = {2025},
volume = {8},
doi = {10.34133/research.0836}
}
EUVIMED